Genital Neoplasms, Female

The grounding supports distinct cancer biology across gynecologic malignancies rather than a single shared mechanism. In ovarian cancer, late presentation, chemoresistance, recurrence, and upregulation of SLC7A11/xCT are highlighted; SLC7A11 can inhibit ferroptosis and support proliferation, invasion, and chemoresistance. The literature also notes immunologic and drug-therapy aspects, including antibody-drug conjugates as a targeted treatment modality in gynecologic cancer.

For vulvar cancer, the supplied guidelines identify increasing age, human papillomavirus infection, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency as risk factors. The other supplied abstracts emphasize advanced-stage presentation and recurrence in ovarian cancer, but do not establish them as risk factors.

Management is described at the modality level and varies by tumor type within female genital neoplasms. For ovarian cancer, traditional treatment involves cytoreductive surgery combined with platinum-based chemotherapy, with newer targeted approaches including antibody-drug conjugates. For endometrial carcinoma and vulvar cancer, the supplied guidelines indicate multidisciplinary management with surgery, radiotherapy, systemic therapy, surveillance, and survivorship care, but do not provide a single unified regimen for the broader disease category.